Alexandria Real Estate Equities, Inc.'s Form 4 filing
Applied Therapeutics, Inc. (APLT) · filed Jun 29, 2022
- Accession no.
- 0001035443-22-000176
- Filed
- Jun 29, 2022, 4:37 PM ET
- Trade date
- Jun 27, 2022
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions and 4 derivative transactions. Open-market purchases total $3.50M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Alexandria Real Estate Equities, Inc.CIK 0001035443 | 10% Owner |
| Alexandria Venture Investments, LLCCIK 0001722024 | 10% Owner |
| Alexandria Equities No. 7, LLCCIK 0001776437 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 27, 2022 | Common Stock | PPurchaseAcquired | +615,000 | $0.9999F1 | +$614,938.5 | 615,000 | Indirect | |
| Jun 27, 2022 | Common Stock | PPurchaseAcquired | +885,000 | $0.9999F1 | +$884,911.5 | 885,000 | Indirect | |
| Jun 27, 2022 | Common Stock | PPurchaseAcquired | +2,050,000 | –F1 | – | 2,050,000 | Indirect | |
| Jun 27, 2022 | Common Stock | PPurchaseAcquired | +2,950,000 | –F1 | – | 2,950,000 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
These securities were purchased at a combined public offering price of $1.00 per share of Common Stock and associated Common Stock Warrant (or, in the case of the Pre-Funded Warrants, $0.9999 per Pre-Funded Warrant and associated Common Stock Warrant).
Referenced by the price of 2 transactions in Table I and 4 transactions in Table II.